<DOC>
	<DOCNO>NCT02785159</DOCNO>
	<brief_summary>Safety Efficacy IDP-118 Lotion Treatment Plaque Psoriasis</brief_summary>
	<brief_title>Safety Efficacy IDP-118 Lotion Treatment Plaque Psoriasis</brief_title>
	<detailed_description>A Phase 2 , Multicenter , Double-Blinded , Randomized , Vehicle-Controlled Study Compare Safety Efficacy IDP-118 Lotion Treatment Plaque Psoriasis</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<criteria>Key Male female , race , least 18 year age ( inclusive ) . Freely provide verbal write informed consent . Has area plaque psoriasis appropriate topical treatment cover Body Surface Area ( BSA ) least 3 % , 12 % . The face , scalp , palm , sol , axilla , intertriginous area exclude calculation . Is willing able avoid prolong exposure treatment area ultraviolet radiation ( natural artificial ) duration study . Has clinical diagnosis psoriasis Baseline visit ( IGA ) Investigator Global Assessment score 3 4 . ( The face , scalp , palm , sol , axillae intertriginous area exclude assessment , psoriasis present . ) Key Has spontaneously improve rapidly deteriorate plaque psoriasis pustular psoriasis , determine investigator . Presents psoriasis treat prescription medication fail respond treatment , even partially temporarily , determine investigator . Presents concurrent skin condition could interfere evaluation treatment area , determine investigator . Is pregnant , nursing infant , plan pregnancy study period . Has receive treatment investigational drug device within 60 day 5 drug halflives ( whichever longer ) prior Baseline visit , concurrently participate another clinical study investigational drug device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>